Ophthalmic Plastic and Reconstructive Surgery · 2021 · 32 citations · 13 references
MedicineImmunologyPathologyImmunotherapyInflammationRheumatologyAnti-inflammatory PharmacologyCrohn Disease PharmacotherapyGastrointestinal InflammationImmune-mediated Inflammatory DiseasesInflammatory Bowel DiseaseInflammatory PathologyColonic InflammationImmune-mediated Intestinal InflammationInflammatory Bowel Disease ImmunopathogenesisInflammatory Bowel Disease PathologyInflammatory Bowel Disease PathophysiologyInflammatory Bowel Disease TherapySymptomatic PresentationTeprotumumab Therapy
A patient with thyroid-associated ophthalmopathy was treated with teprotumumab and developed symptoms concerning for inflammatory bowel disease after her sixth infusion. Colonoscopy was performed, and mucosal biopsies identified evidence of active colitis consistent with a diagnosis of ulcerative colitis. Despite treatment with budesonide and mesalamine, the patient continued to be symptomatic one and a half months after cessation of teprotumumab and required infliximab to achieve good control of her inflammatory bowel disease. This case represents the first report of new-onset inflammatory bowel disease arising during treatment with teprotumumab.
13
Teprotumumab for Thyroid-Associated Ophthalmopathy
Terry J. Smith, George J. Kahaly, Daniel G. Ezra et al. · New England Journal of Medicine · 2017 · 721 citations · Full text
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Raymond S. Douglas, George J. Kahaly, Amy Patel et al. · New England Journal of Medicine · 2020 · 700 citations · Full text
Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 412 citations · Full text